Health ❯ Chronic Conditions

Obesity

Treatment Options Diabetes Weight Management Type 2 Diabetes Inflammation Hypertension Health Risks Comorbidities Weight Loss Medications Weight Loss Drugs

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

Unclear cardiovascular signals together with unfinished manufacturing checks could shape regulators' verdict on Lilly's application.

UCL Review Finds GLP‑1 Drugs Reduce Binge Eating Symptoms

Medicare Launches 18‑Month GLP‑1 Bridge to Cover Weight‑Loss Drugs

Lawmakers Demand Answers After Single Patient Received Experimental Eli Lilly Obesity Drug

Shaquille O’Neal Says Zepbound Has Eased His Obstructive Sleep Apnea

Lilly’s GLP‑1 Sales and PBM Coverage Fuel Record Quarter as Pipeline Logs Durable Wins

PCOS Is Officially Renamed PMOS After Global Consensus

Study Links Longer, Frequent, Morning Naps to Higher Death Risk in Older Adults

GLP-1 Weight-Loss Draws Harsher Stigma Than Lifestyle Change, Study Finds

Stiftung Warentest Backs Only Mounjaro and Wegovy for Durable Weight Loss

Rio Inaugurates Super Health Center, Begins Ozempic Pilot in Public System

67-Year-Old Credits GLP-1 'Microdosing' With Strength Training for Youthful Look as Doctors Urge Caution

Novo Nordisk Sets SUS Wegovy Pilot as Brazil’s Semaglutide Patent Nears Expiry

New Analyses Link GLP-1 Drugs to Modest Bone and Gout Risks, With Mixed Patterns by Diabetes Status

New Guidance on MASLD Puts Lifestyle First, With Coffee and Nuts Showing Potential Benefits

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

Anvisa Issues Safety Alert on GLP‑1 Injection Pens After Six Suspected Pancreatitis Deaths in Brazil

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

‘Seu Boinha’ Remains in ICU After Stroke as Infection Is Diagnosed and Tracheostomy Planned

JAMA Forecast: Nearly Half of U.S. Adults Could Have Obesity by 2035